Vitiligo Treatment Pipeline: 2025 Market Intelligence and Emerging Therapy 

DelveInsight's comprehensive 2025 analysis of the Vitiligo pipeline delivers extensive intelligence on over 18 companies and more than 20 investigational therapies currently advancing through development. This detailed examination encompasses drug candidate profiles across all developmental phases, from preclinical research through clinical trials. The assessment evaluates therapeutic candidates by product classification, developmental phase, administration method, and molecular structure, while also documenting discontinued programs in this therapeutic area.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Vitiligo Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report

Key Highlights from the Pipeline Analysis

• On 10 November 2025, AbbVie launched an investigation to determine the safety profile and therapeutic effectiveness of upadacitinib in individuals diagnosed with non-segmental vitiligo (NSV). The study will monitor adverse reactions and modifications in disease progression.

• On 10 November 2025, Takeda commenced research to assess zasocitinib's safety profile, therapeutic efficacy, and tolerability in adult patients with nonsegmental vitiligo. Study participants will undergo treatment (zasocitinib or placebo) for a maximum duration of 1 year (52 weeks). The placebo formulation mimics the zasocitinib capsule appearance but contains no active pharmaceutical ingredient. Individuals initially receiving placebo will transition to zasocitinib treatment after approximately 6 months.

• On 07 November 2025, Incyte Corporation revealed plans for a phase 3 investigation to examine the safety and therapeutic effectiveness of ruxolitinib cream in pediatric patients diagnosed with nonsegmental vitiligo.

• The current landscape shows a dynamic field with over 18 companies actively advancing more than 20 therapeutic candidates for vitiligo management.

• Key pharmaceutical developers include Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.

• Notable investigational therapies comprise Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and additional candidates.

Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies

Understanding Vitiligo

Vitiligo represents a chronic dermatological disorder characterized by pigment depletion, resulting in smooth, depigmented patches on the skin surface due to melanocyte destruction—the cells responsible for color production. While the precise etiology remains undetermined, the condition is extensively associated with autoimmune mechanisms, wherein the immune system erroneously targets these pigment-producing cells. Typically manifesting on the hands, face, and surrounding bodily orifices, vitiligo can additionally affect hair follicles and mucous membranes. The condition presents in multiple clinical forms, with non-segmental being the predominant type, often displaying symmetrical distribution. Although vitiligo poses no physical health threats and lacks contagious properties, it can significantly influence psychological well-being due to visible cosmetic alterations. Therapeutic interventions concentrate on achieving skin repigmentation or reducing pigment contrast, though treatment outcomes demonstrate considerable individual variation.

Featured Investigational Therapies

Afamelanotide: Clinuvel, Inc. Afamelanotide, developed by Clinuvel, Inc., represents a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) engineered to promote cutaneous pigmentation in vitiligo patients. The compound functions by activating melanocortin 1 receptors (MC1R) on melanocytes, thereby stimulating melanin synthesis and distribution within depigmented skin regions. Afamelanotide is delivered via subcutaneous implant, providing a systemic therapeutic approach that may augment repigmentation outcomes, particularly when combined with controlled UV light therapy. Its mechanism targets the fundamental pigment depletion in vitiligo, aiming to achieve more uniform and effective skin tone restoration. This therapeutic candidate is presently undergoing Phase III clinical assessment for vitiligo treatment.

VYN201: Vyne Therapeutics Inc. Repibresib functions as a pan-bromodomain BET inhibitor engineered for local administration as a "soft" drug to manage conditions involving multiple, diverse inflammatory cellular signaling cascades, while maintaining minimal systemic exposure. BET proteins serve crucial regulatory roles in gene transcription through epigenetic interactions ("reading"). Contemporary research has revealed these proteins' pivotal function in controlling immune cell activation, encompassing T cells and B cells, along with subsequent inflammatory and fibrotic mechanisms. As epigenetic readers, BET proteins govern the recruitment of transcriptional factors essential for producing various pro-inflammatory cytokines. BET inhibitors demonstrate potential for treating numerous immuno-inflammatory and fibrotic disorders by blocking pro-inflammatory cytokine transcription, with additional applications in myeloproliferative neoplastic conditions. Beyond establishing clinical proof-of-concept in vitiligo, repibresib has generated consistent reductions in pro-inflammatory and disease-associated biomarkers alongside improvements in disease severity across several preclinical models (utilizing various administration routes). This compound is currently advancing through Phase II development for vitiligo treatment.

FB102: Forte Biosciences, Inc. FB102 represents a proprietary molecular compound with potentially extensive autoimmune and autoimmune-related therapeutic applications. The Company's FB102 program targets critical pathways implicated in these conditions utilizing a CD122 antagonist. CD122 constitutes a subunit of IL-2/IL-15 receptors functioning as key regulators of NK cells and specific T cell subsets. Substantial reductions in NK cell pharmacodynamic markers of FB102 mechanism were documented, supporting in vitro data alongside NHP studies and FB102's mechanism of action. A phase 1 healthy volunteer SAD/MAD investigation was successfully concluded, demonstrating favorable safety characteristics. This candidate is currently in Phase I development stages for vitiligo treatment.

Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs

Report Coverage and Analysis

This comprehensive pipeline report delivers intelligence on:

• Detailed profiles of pharmaceutical companies developing vitiligo therapeutics, including aggregate therapy portfolios from each organization.

• Assessment of therapeutic candidates classified by early-stage, mid-stage, and late-stage development phases.

• Active and inactive (dormant or discontinued) pipeline programs across participating companies.

• Categorization of investigational drugs by developmental stage, delivery route, target receptor, treatment approach (monotherapy or combination), mechanism of action, and molecular classification.

• In-depth examination of partnerships (industry collaborations and academic alliances), licensing arrangements, and funding details relevant to future market advancement.

Featured Companies

Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others.

Route of Administration Categories

Pipeline products are organized by delivery method:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Molecular Type Classifications

Investigational products are categorized by molecular structure:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Download DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives

Report Scope

• Geographic Coverage: Global

• Featured Companies: Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc. and others

• Pipeline Therapies: Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide and others

• Product Type Assessment: Monotherapy, Combination therapy, Mono/Combination approaches

• Clinical Stage Assessment: Discovery, Preclinical, Phase I, Phase II, Phase III

Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report-access it now! @ Vitiligo Emerging Drugs and Major Companies

Report Structure

1. Introduction

2. Executive Summary

3. Vitiligo: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Vitiligo- DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. Afamelanotide: Clinuvel, Inc.

9. Mid Stage Products (Phase II)

10. VYN201: Vyne Therapeutics Inc.

11. Early Stage Products (Phase I)

12. FB102: Forte Biosciences, Inc.

13. Preclinical and Discovery Stage Products

14. Drug Name: Company Name

15. Inactive Products

16. Vitiligo Key Companies

17. Vitiligo Key Products

18. Vitiligo- Unmet Needs

19. Vitiligo- Market Drivers and Barriers

20. Vitiligo- Future Perspectives and Conclusion

21. Vitiligo Analyst Views

22. Vitiligo Key Companies

23. Appendix

About DelveInsight

DelveInsight operates as a premier healthcare-focused market research and consulting organization, delivering high-caliber market intelligence and analytical insights that empower informed business decision-making. Supported by seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, the firm provides tailored research solutions and strategic insights to a global client base. Engage with our team to access premium-quality, precise, and current intelligence that positions you ahead of market developments.

Contact Us:
Kanishk

kkumar@delveinsight.com